Prokidney Corp. (PROK) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001850270

P/B -0.28

P/E -4.02

P/S 383.63

Market Cap 285.42 Mn

ROIC (Qtr) 17.71

Div Yield % 0.00

Rev 1y % (Qtr) 0.00

Total Debt (Qtr) 4.24 Mn

Debt/Equity (Qtr) 0.00

About

ProKidney Corp., a clinical-stage biotechnology company, is at the forefront of developing innovative treatments for chronic kidney disease (CKD). With a focus on using a patient's own cells for therapy, ProKidney Corp.'s proprietary cell therapy platform has the potential to transform the lives of many individuals suffering from this debilitating disease. ProKidney Corp. is a fully integrated biopharmaceutical company that specializes in developing and commercializing treatments for CKD. Its strategy is to become a leading player in the CKD market...

ProKidney Corp., a clinical-stage biotechnology company, is at the forefront of developing innovative treatments for chronic kidney disease (CKD). With a focus on using a patient's own cells for therapy, ProKidney Corp.'s proprietary cell therapy platform has the potential to transform the lives of many individuals suffering from this debilitating disease.

ProKidney Corp. is a fully integrated biopharmaceutical company that specializes in developing and commercializing treatments for CKD. Its strategy is to become a leading player in the CKD market by developing and commercializing its lead product candidate, REACT, as well as discovering and developing additional product candidates for the treatment of kidney diseases.

The company's business is divided into two main segments: the REACT segment and the preclinical programs segment. The REACT segment includes the development and commercialization of REACT, a cell therapy product candidate for the treatment of CKD caused by type 2 diabetes. The preclinical programs segment includes the development of additional product candidates for the treatment of kidney diseases, including REACT/Gen and REACT/Universal, which are in preclinical development.

ProKidney Corp. has a strong pipeline of product candidates, including REACT, which is in Phase 3 clinical development, as well as multiple Phase 2 clinical trials. The company has also completed a Phase 1 clinical trial of REACT in patients with CKD caused by congenital anomalies of the kidney and urinary tract.

The company's manufacturing facility is designed to comply with current good manufacturing practices (cGMP) and is capable of manufacturing product for clinical trials and commercial launch. ProKidney Corp. plans to expand its manufacturing footprint to meet demand for REACT upon commercialization.

ProKidney Corp. is a leader in the development of cell therapy products for the treatment of CKD, with a strong pipeline of product candidates and a focus on developing innovative treatments for this disease. The company's REACT product candidate has shown promising results in clinical trials, and the company is poised to make a significant impact in the treatment of CKD.

The company's competitive advantages include its proprietary cell therapy platform, its strong pipeline of product candidates, and its experienced management team. ProKidney Corp. is well-positioned to capitalize on the growing demand for innovative treatments for CKD, and its products have the potential to significantly improve patient outcomes.

The company's customers include patients with CKD, as well as healthcare providers and payors. The company's products are designed to improve patient outcomes and reduce healthcare costs, making it an attractive option for patients and healthcare providers.

In the company's Phase 3 clinical development program, two studies are currently underway: PROACT 1 and PROACT 2. PROACT 1 is a randomized, blinded, sham control arm, bi-lateral kidney dose, controlled efficacy study of REACT in subjects with CKD caused by type 2 diabetes. PROACT 2 is a planned Phase 3, randomized, blinded, bi-lateral kidney dose, sham control arm, controlled efficacy study of REACT in subjects with CKD caused by type 2 diabetes.

ProKidney Corp. faces potential competition from many different sources, including major and specialty pharmaceutical and biotechnology companies, as well as developers of tubular and glomerular cell drug modulators, e.g., SGLT2 inhibitors, antifibrosis medications, e.g., Mineralocorticoid Receptor Antagonists (MRAs), glucose-dependent insulin release stimulators, e.g., GLP-1 agonists, induced pluripotent cells, other autologous mesenchymal stem cells, and mechanical renal assist devices such as implantable devices and wearable renal dialysis machines.

The company's intellectual property strategy includes seeking patent protection in the United States and in jurisdictions outside of the United States related to its proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of its business. The company also relies on trade secrets, know-how, continuing technological innovation, and potential in-licensing opportunities to develop and maintain its proprietary position.

Stock Price Chart

Analysis

Pros

Healthy cash reserves of 95.32M provide 96.19x coverage of short-term debt 991000, demonstrating strong liquidity position and minimal refinancing risk.
Strong tangible asset base of 351.61M provides 83x coverage of total debt 4.24M, indicating robust asset backing and low credit risk.
Short-term investments of 176.40M provide solid 6.75x coverage of other current liabilities 26.13M, indicating strong liquidity.
Tangible assets of 351.61M provide robust 13.46x coverage of other current liabilities 26.13M, indicating strong asset backing.
Cash reserves of 95.32M provide robust 3.28x coverage of current liabilities 29.06M, indicating strong short-term solvency.

Cons

Operating cash flow of (111.78M) barely covers its investment activities of 90.95M, with a coverage ratio of -1.23, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
Investment activities of 90.95M provide weak support for R&D spending of 119.75M, which is 0.76x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
The company's operating cash flow of (111.78M) shows concerning coverage of stock compensation expenses of 26.58M, with a -4.21 ratio indicating potential earnings quality issues.
Free cash flow of (146.73M) provides weak coverage of capital expenditures of 34.95M, with a -4.20 ratio suggesting additional external financing needs for growth initiatives.
Operating cash flow of (111.78M) provides minimal -30.20x coverage of tax expenses of 3.70M, suggesting potential tax planning inefficiencies or unsustainable tax positions.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,349.40 Bn	-1,464.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	437.43 Bn	6,381.20	87.97	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.09 Bn	31.59	9.90	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.10 Bn	17.06	5.48	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	55.87 Bn	1,282.42	17.40	3.21 Bn
6	ARGX	Argenx Se	52.85 Bn	35.08	27,559.65	-
7	BNTC	Benitec Biopharma Inc.	41.75 Bn	-998.33	0.00	0.00 Bn
8	INSM	INSMED Inc	37.80 Bn	-31.93	84.56	0.74 Bn

Industry Comparisons

Current Valuation

Metric	Value	Industry
EV to Assets	0.58	12.31
EV to Cash from Ops.	-1.83	23.25
EV to Debt	48.37	738.44
EV to EBIT	-3.04	-9.16
EV to EBITDA	-1.24	6.95
EV to Free Cash Flow [EV/FCF]	-1.40	21.90
EV to Market Cap	0.72	65.67
EV to Revenue	275.41	227.32
Price to Book Value [P/B]	-0.28	22.34
Price to Earnings [P/E]	-4.02	-11.77

Dividend Metrics

Metric	Value	Industry
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	-13,465.40	841.00

Growth Metrics

Metric	Value	Industry
Capex Growth (1y) %	-527.30	-27.13
Cash and Equivalents Growth (1y) %	-11.81	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	-55.77	-46.93
EBITDA Growth (1y) %	-8.98	-1.68
EBIT Growth (1y) %	-49.26	-56.45
EBT Growth (1y) %	-49.24	-12.70
EPS Growth (1y) %	0.00	-28.31
FCF Growth (1y) %	-10.21	-31.90
Gross Profit Growth (1y) %	0.00	226.84

Liquidity Ratios

Metric	Value	Industry
Asset Utilization Ratio	0.00	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	3.28	3.85
Current Ratio	10.32	7.27
Debt to Equity Ratio	0.00	0.40
Interest Cover Ratio	-13,465.40	841.00
Times Interest Earned	-13,465.40	841.00

Profitability

Metric	Value	Industry
EBITDA Margin %	-8,200.90	-18,234.31
EBIT Margin %	-9,049.33	-18,580.80
EBT Margin %	-9,050.00	-19,488.74
Gross Margin %	100.00	-7.59
Net Profit Margin %	-9,547.40	-19,439.22

Prokidney Corp. (NASDAQ: PROK)